Zortress Approval Delay Caused By Novartis Attempts To Avoid Controlled Trial Of Dosing Regimen
This article was originally published in Pharmaceutical Approvals Monthly
Sponsors cannot cut corners in developing clinical data to support a revised dosing scheme, even when a drug’s efficacy has already been shown, Novartis learned while shepherding its kidney transplant agent Zortress (everolimus) through the FDA approval process.
You may also be interested in...
Traditional endpoints are becoming increasingly difficult to use successfully in clinical trials because the standard of care has become highly effective.
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
Although often overshadowed by the novelty of FDA’s sweeping authority in constructing Risk Evaluation and Mitigation Strategies, examination of agency review documents suggest that the FDA Amendments Act’s other safety innovation, granting FDA the ability to require (i.e., enforce) post-marketing studies, is increasingly important to the approval of NDAs with marginal data on issues of concern.